|
Market Closed -
Nasdaq
16:00:00 2026-09-16 EDT
|
5-day change | 1st Jan Change | ||
| 5.990 USD | -6.11% |
|
-5.82% | -43.97% |
| 08-27 | Outlook Therapeutics Appoints Kevin Lundquist as CFO | MT |
| 08-13 | CapsoVision, Inc., Q2 2026 Earnings Call, Aug 13, 2026 |
Evolution of the Average Target: CapsoVision, Inc.
Evolution of the Target Price: CapsoVision, Inc.
Changes in Analyst Recommendations: CapsoVision, Inc.
ad8cf2c5e326f3d764c5cfc207.eTuRrG7kI1WLpwN30LEEbbg3WAlLDOMBsROF29pJ3fE.EGnJnSmVWzfm30IRgYBlI-B9Bz8FO5NU1j6xkJMd6qNPY6jfKNdCZ7vTMw~901d1a7c2c09d9a478c577fc952501da
| Consensus | Analysts' recommendations evolution (4 months) | Financial estimates divergence | Analysts' Target price divergence | Objective/dr gap | ||
|---|---|---|---|---|---|---|
 | - | +48.9% | ||||
| +53.72% | |||||
| +39.62% | |||||
| +53.74% | |||||
| - | +43.19% | ||||
| Average | +47.83% | |||||
| Weighted average by Cap. | +49.98% |
Analysts' Consensus
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
6.380USD
Average target price
9.500USD
Spread / Average Target
+48.90%
High Price Target
10.00USD
Spread / Highest target
+56.74%
Low Price Target
9.000USD
Spread / Lowest Target
+41.07%
Analyst Consensus Detail
Consensus revision (last 18 months)
- Stock Market
- Stocks
- CV Stock
- Consensus CapsoVision, Inc.
Select your edition
All financial news and data tailored to specific country editions
